Lineage Cell Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Lineage Cell Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.56M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $9.50M | Mar 5, 2026 |
| FY2023 | Dec 31, 2023 | $2.09M | Mar 7, 2024 |
| FY2023 | Sep 30, 2023 | $1.25M | Mar 7, 2024 |
| FY2023 | Jun 30, 2023 | $3.23M | Mar 7, 2024 |
| FY2023 | Mar 31, 2023 | $2.39M | Mar 7, 2024 |
| FY2023 | Dec 31, 2022 | $1.92M | Mar 7, 2024 |
| FY2023 | Sep 30, 2022 | $3.00M | Mar 7, 2024 |
| FY2023 | Jun 30, 2022 | $4.55M | Mar 7, 2024 |
| FY2023 | Mar 31, 2022 | $5.24M | Mar 7, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.56M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $9.50M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $8.95M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $14.70M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $4.34M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $1.83M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $3.52M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $4.99M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $3.46M | Mar 14, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $945.0K | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | $1.64M | Mar 15, 2018 |
| FY2017 | Jun 30, 2017 | $376.0K | Mar 15, 2018 |
| FY2017 | Mar 31, 2017 | $333.0K | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $1.10M | Mar 15, 2018 |
| FY2017 | Sep 30, 2016 | $1.44M | Mar 15, 2018 |
| FY2017 | Jun 30, 2016 | $1.17M | Mar 15, 2018 |
| FY2017 | Mar 31, 2016 | $1.85M | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $1.31M | Mar 16, 2017 |
| FY2016 | Sep 30, 2015 | $1.87M | Mar 16, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $8.27M | Mar 7, 2024 |
| FY2023 | Dec 31, 2022 | $13.98M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $2.92M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $1.44M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $3.10M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $4.69M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $3.29M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $5.57M | Mar 15, 2018 |
| FY2017 | Dec 31, 2015 | $5.93M | Mar 15, 2018 |
| FY2016 | Dec 31, 2014 | $4.41M | Mar 16, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($63.53M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($18.61M) | Mar 5, 2026 |
| FY2023 | Dec 31, 2023 | ($4.78M) | Mar 7, 2024 |
| FY2023 | Sep 30, 2023 | ($7.11M) | Mar 7, 2024 |
| FY2023 | Jun 30, 2023 | ($5.23M) | Mar 7, 2024 |
| FY2023 | Mar 31, 2023 | ($4.37M) | Mar 7, 2024 |
| FY2023 | Dec 31, 2022 | ($6.35M) | Mar 7, 2024 |
| FY2023 | Sep 30, 2022 | ($6.07M) | Mar 7, 2024 |
| FY2023 | Jun 30, 2022 | ($6.76M) | Mar 7, 2024 |
| FY2023 | Mar 31, 2022 | ($7.09M) | Mar 7, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($36.62M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($21.48M) | Mar 5, 2026 |
| FY2023 | Dec 31, 2023 | ($6.36M) | Mar 7, 2024 |
| FY2023 | Sep 30, 2023 | ($6.71M) | Mar 7, 2024 |
| FY2023 | Jun 30, 2023 | ($5.02M) | Mar 7, 2024 |
| FY2023 | Mar 31, 2023 | ($6.64M) | Mar 7, 2024 |
| FY2023 | Dec 31, 2022 | ($6.64M) | Mar 7, 2024 |
| FY2023 | Sep 30, 2022 | ($5.25M) | Mar 7, 2024 |
| FY2023 | Jun 30, 2022 | ($4.23M) | Mar 7, 2024 |
| FY2023 | Mar 31, 2022 | ($6.40M) | Mar 7, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.73M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $12.47M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $15.71M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $13.99M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $33.91M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $12.32M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $17.95M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $20.96M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $24.02M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $36.11M | Mar 15, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.92M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($23.09M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($28.57M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $1.06M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($23.56M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($19.75M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($31.95M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($30.88M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($30.52M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($42.33M) | Mar 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $522.0K | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $565.0K | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $674.0K | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $413.0K | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $340.0K | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $64.0K | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $440.0K | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $556.0K | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $1.33M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $2.25M | Mar 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $112.58M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $113.22M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $101.02M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $123.66M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $174.55M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $107.95M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $125.48M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $101.66M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $173.24M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $142.57M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.24M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $36.21M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $39.00M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $51.73M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $83.65M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $12.82M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $14.23M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $9.41M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $8.98M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $12.06M | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.55M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $78.38M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $63.42M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $73.34M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $92.22M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $96.20M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $112.96M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $93.84M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $162.64M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $117.93M | Mar 15, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.67M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $10.67M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $10.67M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $10.67M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $10.67M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $10.67M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $10.67M | Mar 11, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($467.00M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($403.47M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($384.86M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($363.37M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($337.10M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($294.08M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($273.42M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($261.86M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($216.30M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($196.32M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.79M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $45.79M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $35.44M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $11.36M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $55.74M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $32.59M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $9.50M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $23.59M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $36.84M | Mar 14, 2019 |
| FY2018 | Dec 31, 2016 | $22.09M | Mar 14, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 5, 2026 |
| FY2023 | Dec 31, 2023 | 0 | Mar 7, 2024 |
| FY2023 | Sep 30, 2023 | 0 | Mar 7, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Mar 7, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Mar 7, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Mar 7, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Mar 7, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Mar 7, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Mar 7, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 5, 2026 |
| FY2023 | Dec 31, 2023 | 0 | Mar 7, 2024 |
| FY2023 | Sep 30, 2023 | 0 | Mar 7, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Mar 7, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Mar 7, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Mar 7, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Mar 7, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Mar 7, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Mar 7, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 243.12M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 220.42M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 174.99M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | 170.09M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 169.48M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 153.10M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | 149.80M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | 127.14M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | 126.87M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | 102.78M | Mar 15, 2018 |